Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

A Global Alliance Established for Sharing Genomic Data

By BiotechDaily International staff writers
Posted on 24 Jun 2013
A shared framework for analyzing and distributing genomic information should soon speed medical progress and innovations.

Nearly 70 organizations in research, healthcare, and disease advocacy have agreed to take part in a global alliance focused on standardizing and sharing genomic and clinical data. “The cost of genome sequencing has fallen one-million fold in the past several years, fueling an explosion of information about the genetic basis of human health and disease,” wrote the authors of a white report announcing the alliance. In principle, this plethora of genome data could reveal the genetic basis of inherited and infectious disease, cancer, and drug responses. “However, we are not organized to seize this extraordinary opportunity.”

The problem is that the data are “collected and studied in silos: by disease, by institution, and by country,” reported the investigators. Tools and techniques for study are not standardized and can be incompatible. Furthermore, there are not agreed upon regulatory procedures that respect the privacy of people who have donated their genome sequences to research projects. All this “inhibits learning and improving healthcare,” they reported.

To address these problems, the alliance will develop international standards and infrastructure to share and integrate data in a controlled, secure, and interpretable way that upholds patient autonomy and right to privacy. Participants in the accord include the US National Institutes of Health (Bethesda, MD, USA), the Wellcome Trust Sanger Institute (Hinxton, Cambridgeshire, UK), and the Beijing Genomics institute (BGI; Beijing, China), as well as universities and hospitals.

The large pool of genomic sequences and medical data expected from the alliance is the sort of dataset required to determine the genetic basis of both cancer and rare diseases, recently reported an item in the New York Times. The mutations underlying these disorders are just too rare to be studied in data collected at a single institution.

A disease might occur in one in 1,000 or one in 100,000 babies, according to Dr. David Altshuler, deputy director and chief academic officer at the Broad Institute of Harvard University (Cambridge, MA, USA) and the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA). A medical center might never see a child with that disease, or might see just one. “Since everyone sees zero or one, no one ever learns,” Dr. Altshuler said.

In spite of the commendable goals of the alliance, researchers may be reluctant to share hard-won genomic information, a “valuable commodity,” the researcher noted. A big question for the group is whether it can convince institutions to share their most meaningful data. “The mission is unquestionably worthy,” said cardiologist Dr. Eric Topol, director of the Scripps Translational Science Institute (La Jolla, CA, USA), which has not yet considered joining the alliance. But, he adds, “it means taking the walls down, and that’s tricky—because you’ve got each center wanting to hold on to its own data, and the loss of control is a very difficult concept.”

Related Links:
US National Institutes of Health
Wellcome Trust Sanger Institute
Massachusetts Institute of Technology



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.